TRPM3 and myalgic encephalomeyelitis/chronic fatigue syndrome: Pathological differentiation of TRPM7 in ME/CFS may follow the dysregulation of metabolism or cellular mechanisms secondary to known TRPM3 and Ca2+ signalling impairments, epigenetic modulation of TRPM7, or post-translational modifications of the TRPM7 protein that influence the susceptibility of developing neuroimmune dysfunction.